시장보고서
상품코드
1630690

자궁내막암 시장 규모, 점유율, 성장 분석 : 암 유형별, 치료법별, 진단 방법별, 스테이지별, 최종 용도별, 지역별 - 산업 예측(2025-2032년)

Endometrial Cancer Market Size, Share, Growth Analysis, By Cancer Type (Endometrial carcinoma, Uterine sarcoma), By Treatment (Surgery, Chemotherapy), By Diagnosis Method, By Stage, By End Use, By Region - Industry Forecast 2025-2032

발행일: | 리서치사: SkyQuest | 페이지 정보: 영문 157 Pages | 배송안내 : 3-5일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 자궁내막암 시장 규모는 2023년에 286억 9,000만 달러에 달하며, 예측 기간(2025-2032년)의 CAGR은 4.9%로, 2024년 301억 달러에서 2032년에는 441억 3,000만 달러로 성장할 전망입니다.

세계의 자궁내막암 시장은 발병률 증가, 인식 제고, 의료 인프라 강화에 힘입어 강력한 성장세를 보이고 있습니다. 분자 프로파일링 및 유전자 검사를 포함한 진단 툴의 혁신은 보다 정확하고 맞춤화된 치료 옵션으로 이어지고 있습니다. 표적치료제, 면역치료제, 병용요법의 출현으로 치료 성적이 개선되면서 시장은 더욱 확대되고 있습니다. 유전체 프로파일링과 액체생검과 같은 발전은 조기 발견과 맞춤형 치료 접근법을 촉진하고 있습니다. 그러나 높은 치료 비용, 고급 의료 서비스에 대한 제한된 접근성, 효과적인 조기 발견 방법의 시급한 필요성 등은 자궁내막암이 전 세계에 미치는 영향에 대처하는 데 있으며, 여전히 큰 걸림돌로 작용하고 있습니다.

목차

서론

  • 조사의 목적
  • 조사 범위
  • 정의

조사 방법

  • 정보 조달
  • 2차 데이터와 1차 데이터 방법
  • 시장 규모 예측
  • 시장의 전제조건과 제한

개요

  • 세계 시장 전망
  • 공급과 수요의 동향 분석
  • 부문별 기회 분석

시장 역학과 전망

  • 시장 개요
  • 시장 규모
  • 시장 역학
    • 촉진요인과 기회
    • 억제요인과 과제
  • Porter의 산업 분석

주요 시장 인사이트

  • 주요 성공 요인
  • 경쟁의 정도
  • 주요 투자 기회
  • 시장 에코시스템
  • 시장의 매력 지수(2024년)
  • PESTEL 분석
  • 거시경제 지표
  • 밸류체인 분석
  • 가격 분석

자궁내막암 시장 규모 : 암 유형별

  • 시장 개요
  • 자궁내막암
    • 선암
    • 암육종
    • 편평 상피암
    • 기타 유형 암
  • 자궁육종

자궁내막암 시장 규모 : 치료법별

  • 시장 개요
  • 수술
  • 화학요법
  • 방사선 치료
  • 호르몬 요법
  • 표적치료
  • 면역치료

자궁내막암 시장 규모 : 진단 방법별

  • 시장 개요
  • 생검
  • 골반 초음파 검사
  • 자궁경 검사
  • CT 스캔
  • 기타 진단 방법

자궁내막암 시장 규모 : 스테이지별

  • 시장 개요
  • 스테이지 I
  • 스테이지 II
  • 스테이지 III
  • 스테이지 IV

자궁내막암 시장 규모 : 최종 용도별

  • 시장 개요
  • 병원
  • 암센터
  • 외래 수술 센터

자궁내막암 시장 규모

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 독일
    • 스페인
    • 프랑스
    • 영국
    • 이탈리아
    • 기타 유럽 지역
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 한국
    • 기타 아시아태평양
  • 라틴아메리카
    • 브라질
    • 기타 라틴아메리카 지역
  • 중동 및 아프리카
    • GCC 국가
    • 남아프리카공화국
    • 기타 중동 및 아프리카

경쟁 정보

  • 상위 5사의 비교
  • 주요 기업의 시장 포지셔닝(2024년)
  • 주요 시장 기업이 채택한 전략
  • 시장의 최근 동향
  • 기업의 시장 점유율 분석(2024년)
  • 주요 기업의 기업 개요
    • 회사 개요
    • 제품 포트폴리오 분석
    • 부문별 점유율 분석
    • 매출의 전년대비 비교(2022-2024)

주요 기업 개요

  • GlaxoSmithKline plc(GSK)(United Kingdom)
  • Merck & Co., Inc.(United States)
  • Notable Product : Keytruda(pembrolizumab)
  • AstraZeneca plc(United Kingdom)
  • Notable Product : Imfinzi(durvalumab)
  • Novartis AG(Switzerland)
  • Pfizer Inc.(United States)
  • F. Hoffmann-La Roche AG(Switzerland)
  • Bristol Myers Squibb Company(United States)
  • Karyopharm Therapeutics Inc.(United States)
  • Siemens Healthineers AG(Germany)
  • Takeda Pharmaceutical Company Limited(Japan)
  • Incyte Corporation(United States)
  • Context Therapeutics Inc.(United States)
  • Evergreen Therapeutics, Inc.(United States)
  • Sysmex Corporation(Japan)
  • Gilead Sciences, Inc.(United States)
  • Johnson & Johnson(United States)
  • AbbVie Inc.(United States)
  • Sanofi S.A.(France)

결론과 권장사항

KSA 25.02.20

Global Endometrial Cancer Market size was valued at USD 28.69 billion in 2023 and is poised to grow from USD 30.1 billion in 2024 to USD 44.13 billion by 2032, growing at a CAGR of 4.9% during the forecast period (2025-2032).

The global endometrial cancer market is experiencing robust growth, fueled by rising incidence rates, heightened awareness, and enhanced healthcare infrastructure. Innovations in diagnostic tools, including molecular profiling and genetic testing, are leading to more precise and personalized treatment options. The market is further expanding due to the emergence of targeted therapies, immunotherapies, and combination treatment modalities that provide improved outcomes. Advancements such as genomic profiling and liquid biopsies facilitate early detection and tailored treatment approaches. Nevertheless, challenges like high treatment costs, limited access to advanced healthcare services, and the pressing need for effective early detection methods continue to pose significant hurdles in addressing the global impact of endometrial cancer.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Endometrial Cancer market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Endometrial Cancer Market Segmental Analysis

Global Endometrial Cancer Market is segmented by Cancer Type, Treatment, Diagnosis Method, Stage, End Use and region. Based on Cancer Type, the market is segmented into Endometrial carcinoma and Uterine sarcoma. Based on Treatment, the market is segmented into Surgery, Chemotherapy, Radiation therapy, Hormone therapy, Targeted therapy and Immunotherapy. Based on Diagnosis Method, the market is segmented into Biopsy, Pelvic Ultrasound, Hysteroscopy, CT Scan and Other Diagnosis Methods. Based on Stage, the market is segmented into Stage I, Stage II, Stage III and Stage IV. Based on End Use, the market is segmented into Hospitals, Cancer centers and Ambulatory surgical centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Endometrial Cancer Market

The global endometrial cancer market is significantly driven by the rising incidence of this prevalent gynecological cancer. Factors such as obesity, hormonal imbalances, and diabetes are contributing to a steady increase in cases, prompting a growing need for effective diagnostic and therapeutic options. This heightened demand for solutions not only accelerates market growth but also emphasizes the importance of advancements in medical technology and enhanced screening methods. These innovations facilitate early detection and treatment of endometrial cancer, ultimately leading to improved patient outcomes and further stimulating investments in healthcare infrastructure to combat this escalating health concern.

Restraints in the Global Endometrial Cancer Market

One significant challenge facing the global endometrial cancer market is the combination of high treatment costs and restricted healthcare accessibility, particularly in developing countries. The financial burden associated with treatment options like surgeries, chemotherapy, and radiation therapy can be overwhelming for many patients, especially those lacking sufficient health insurance or financial resources. Furthermore, in various regions, inadequate healthcare infrastructure, including a shortage of diagnostic services and specialized professionals, complicates the timely and effective treatment of endometrial cancer. To enhance patient outcomes worldwide, it is essential to tackle these obstacles by improving both the affordability and accessibility of quality healthcare.

Market Trends of the Global Endometrial Cancer Market

The Global Endometrial Cancer market is experiencing a notable trend of increased collaborations and partnerships among pharmaceutical companies and research institutions, aimed at expediting drug development and clinical trials. This strategic synergy enhances the focus on innovative diagnostics and the introduction of novel therapeutic options, ultimately translating into improved patient outcomes. Moreover, the rising incidence of endometrial cancer and heightened awareness surrounding women's health are driving the demand for advanced treatment solutions. As stakeholders prioritize research investments and regulatory approvals, this collaborative landscape is likely to foster a dynamic market, positioning it for accelerated growth in the coming years.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2024
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis

Global Endometrial Cancer Market Size by Cancer Type & CAGR (2025-2032)

  • Market Overview
  • Endometrial carcinoma
    • Adenocarcinoma
    • Carcinosarcoma
    • Squamous Cell Carcinoma
    • Other Types of Cancer
  • Uterine sarcoma

Global Endometrial Cancer Market Size by Treatment & CAGR (2025-2032)

  • Market Overview
  • Surgery
  • Chemotherapy
  • Radiation therapy
  • Hormone therapy
  • Targeted therapy
  • Immunotherapy

Global Endometrial Cancer Market Size by Diagnosis Method & CAGR (2025-2032)

  • Market Overview
  • Biopsy
  • Pelvic Ultrasound
  • Hysteroscopy
  • CT Scan
  • Other Diagnosis Methods

Global Endometrial Cancer Market Size by Stage & CAGR (2025-2032)

  • Market Overview
  • Stage I
  • Stage II
  • Stage III
  • Stage IV

Global Endometrial Cancer Market Size by End Use & CAGR (2025-2032)

  • Market Overview
  • Hospitals
  • Cancer centers
  • Ambulatory surgical centers

Global Endometrial Cancer Market Size & CAGR (2025-2032)

  • North America (Cancer Type, Treatment, Diagnosis Method, Stage, End Use)
    • US
    • Canada
  • Europe (Cancer Type, Treatment, Diagnosis Method, Stage, End Use)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Cancer Type, Treatment, Diagnosis Method, Stage, End Use)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Cancer Type, Treatment, Diagnosis Method, Stage, End Use)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Cancer Type, Treatment, Diagnosis Method, Stage, End Use)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2024
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2024
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

  • GlaxoSmithKline plc (GSK) (United Kingdom)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck & Co., Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Notable Product: Keytruda (pembrolizumab)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca plc (United Kingdom)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Notable Product: Imfinzi (durvalumab)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • F. Hoffmann-La Roche AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bristol Myers Squibb Company (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Karyopharm Therapeutics Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Siemens Healthineers AG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Takeda Pharmaceutical Company Limited (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Incyte Corporation (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Context Therapeutics Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Evergreen Therapeutics, Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sysmex Corporation (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Gilead Sciences, Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Johnson & Johnson (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AbbVie Inc. (United States)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sanofi S.A. (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제